Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNK01 (natural killer cells) plus pembrolizumab in stage IV NSCLC after platinum failure
KCT0003463Phase 2Completed
- Sponsor
- NKMax Co., Ltd.
- Start
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of troculeucel, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by NKMax Co., Ltd.. Started Feb 2019; status: completed.
02
Drugs
troculeucelpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0003463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003463.